UNSPSC 51285405: Cefrotil

This classification denotes a cephalosporin antibiotic with the molecular formula C20H22N4O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 44P98H0A27, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-methyl-8-oxo-7-(((4-(1,4,5,6-tetrahydro-2-pyrimidinyl)phenyl)acetyl)amino)-, (6r,7r)- but more generally known as cefrotil, which bears US NIH Compound Identifier 68692.

UNSPSC 51285405 Cefrotil is a Commodity code for a specific antibiotic pharmaceutical, but recent state and local procurement activity under this code does not align with the generic product name — instead, issuing bodies are buying naloxone, medical and first aid supplies for emergency responders, generic pharmaceuticals through cooperative purchasing agreements, and implementing direct-to-manufacturer prescription programs. The actual work solicited ranges from standalone naloxone procurement and drug deactivation systems for community health to broad-based generic pharmaceutical supply contracts serving multiple state and local facilities through authorized wholesalers, and exploratory market research on pharmacy benefit program restructuring.

Recent opportunities span Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, estimated at fixed-fee pricing with potential FEMA funding. The City of Tampa released an IFB (26P00145, due March 13, 2026) for medical and first aid supplies serving the Tampa Fire Department Rescue Division across 169 line items with an estimated contract value of $700,000.00 and a designated small local business enterprise set-aside with a 5 percent bid discount up to $10,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across state and local government facilities in Minnesota and Oregon, with products to be supplied through three authorized wholesalers and weighted evaluation favoring price competitiveness at 75 percent. The Texas Health and Human Services Commission issued an RFI (HHS0017013, due April 3, 2026) to gather vendor capabilities on implementing a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, functioning as preliminary market research prior to formal competitive solicitation.